866-997-4948(US-Canada Toll Free)

Precose (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 42 Pages


GlobalDatas pharmaceuticals report, Precose (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Precose sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Precose including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Precose including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2002-2020 for Precose in the seven major markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 19

6.1 Insulin 19
6.2 Oral Medications 19
6.2.1 Sulfonylureas (SUR) 19
6.2.2 Biguanides (BGDs) 19
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 21
6.2.4 Meglitinides 21
6.2.5 Thiazolidinediones (TZDs) 22
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 23
6.2.7 Oral Combination Therapy 23
6.3 Other Injectionable Medications 24
6.3.1 Pramlintide 24
6.3.2 Exenatide 24
6.4 Market Share as per Classes in Type 2 Diabetes 24

7 Precose 25
7.1 Introduction 25
7.2 Mechanism of Action 25
7.3 Clinical Studies 25
7.3.1 Phase III Clinical Trial Evaluating Precose/Glucobay in NIDDM Patients after Dietry Treatment Only. 25
7.3.2 Phase III Clinical Trial Evaluating Precose/Glucobay in NIDDM Patients Receiving Sulfonylureas. 25
7.3.3 Precose/Glucobay in NIDDM Patients Receiving Metformin 26
7.4 Approval History of Precose 27
7.5 Factors Affecting Sales of Precose 27
7.5.1 Safety Profile 27
7.5.2 Low Efficacy 27
7.5.3 No Weight Gain 27
7.5.4 Patent Expiry of Precose 27
7.6 Drug Evaluation 28
7.6.1 Drug Risk Benefit Score 28
7.6.2 Intensity of Competition 28
7.7 Sales Estimates 29
7.7.1 Target Patient Pool for Precose 29
7.7.2 Dosing 29
7.7.3 Market Penetration 29
7.7.4 Annual Cost of Therapy 29
7.7.5 Sales Estimates of Precose 30

8 Diabetes Market: Appendix 39
8.1 Market Definitions 39
8.2 List of Abberiviations 39
8.3 Research Methodology 39
8.3.1 Coverage 40
8.3.2 Secondary Research 40
8.3.3 Forecasting 40
8.3.4 Net Penetration of Drug 41
8.3.5 Net Annual Dosing 41
8.3.6 Annual Cost of Therapy 41
8.3.7 Primary Research 41
8.3.8 Expert Panels 41
8.4 Contact Us 42
8.5 Disclaimer 42
8.6 Sources 42

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 10: Mean Change in HbA1c From Fixed Dose Monotherapy Studies 25
Table 11: Mean Change in HbA1c From Combination Trial of Precose and Sulfonylureas 26
Table 12: Approval History of Precose 27
Table 13: Drug Risk Benefit Score of Precose 28
Table 15: Precose, Type 2 Diabetes, Global, Sales Estimates ($m), 20022015 30
Table 16: Precose, Type 2 Diabetes, The US, Sales Estimates ($m), 20022015 31
Table 17: Precose, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022015 32
Table 18: Precose, Type 2 Diabetes, France, Sales Estimates ($m), 20022015 33
Table 19: Precose, Type 2 Diabetes, Germany, Sales Estimates ($m), 20022015 34
Table 20: Precose, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022015 35
Table 21: Precose, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022015 36
Table 22: Precose, Type 2 Diabetes, Japan, Sales Estimates ($m), 20022015 37

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylurea 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 24
Figure 12: Precose, Type 2 Diabetes, Global, Sales Estimates ($m), 20022015 30
Figure 13: Precose, Type 2 Diabetes, The US, Sales Estimates ($m), 20022015 31
Figure 14: Precose, Type 2 Diabetes, The UK, Sales Estimates ($m), 20022015 32
Figure 15: Precose, Type 2 Diabetes, France, Sales Estimates ($m), 20022015 33
Figure 16: Precose, Type 2 Diabetes, Germany, Sales Estiamtes ($m), 20022015 34
Figure 17: Precose, Type 2 Diabetes, Italy, Sales Estimates ($m), 20022015 35
Figure 18: Precose, Type 2 Diabetes, Spain, Sales Estimates ($m), 20022015 36
Figure 19: Precose, Type 2 Diabetes, Japan, Sales Estimates ($m), 20022015 37
Figure 20: Precose, Type 2 Diabetes, Global, Sales Distribution by Country (%), 2007 38

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *